comparemela.com

Latest Breaking News On - நிறுவனம் கியூரி - Page 2 : comparemela.com

SARS-CoV-2 interacts with unusual RNA structures in human cells

SARS-CoV-2 interacts with unusual RNA structures in human cells The study, published in the journal Nucleic Acids Research, demonstrated that G4 ligands, the chemical that binds with G4s, prevent this interaction. The results could pave the way for developing inhibitors of these interactions as potential antiviral compounds. SARS-CoV-2 The SARS-CoV-2, the virus behind the coronavirus disease (COVID-19) pandemic, continues to spread across the globe, infecting over 194 million people. The pandemic has claimed more than 4.16 million lives. The SARS-CoV-2 genome contains 14 open reading frames, with ORF1a and ORF1b occupying two-thirds of the genome and encoding 16 non-structural proteins (Nsp1-16). Among these, the Nsp3 proteins play a pivotal role in the formation and activity of the viral replication complex.

PEP-Therapy Raises €2 6M in Series A Extension Financing

PEP-Therapy Raises €2 6M in Series A Extension Financing
finsmes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finsmes.com Daily Mail and Mail on Sunday newspapers.

PEP-Therapy extends Series-A financing, raising a total of €5 4 million to progress the clinical development of its lead candidate PEP-010

as well as a €1 million loan from Bpifrance PARIS, July 19, 2021 /PRNewswire/   PEP-Therapy, a biotechnology company developing cell penetrating peptides as targeted therapies for the treatment of cancers, announced today that it raised an additional €2.6 million ($3 million) in an extension of its Series A financing round, bringing the total raised in this round to €5.4 million ($6.4 million). This new funding comprises €1.6 million in equity from Anaxago, i&i Prague and BADGE as well as a €1 million loan from Bpifrance. This increased financial support highlights the potential of PEP-010, as well as PEP-Therapy s Cell Penetrating & Interfering Peptide (CP&IP) technology platform, which was first developed at Sorbonne University and Institut Curie.

PEP-Therapy extends Series-A financing, raising a total of €5 4 million to progress the clinical development of its lead candidate PEP-010

PEP-Therapy extends Series-A financing, raising a total of €5 4 million to progress the clinical development of its lead candidate PEP-010
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.